Publications by authors named "Alan B Sandler"

Claim this Profile
I
Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancer.
Mitchell S von Itzstein, Sawsan Rashdan, Suzanne E Dahlberg, David E Gerber, Alan B Sandler

Oncologist· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
Josep Garcia, Herbert I Hurwitz, Alan B Sandler, David Miles, Robert L Coleman

Cancer Treat Rev· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials.
Corey J Langer, Mark A Socinski, Jyoti D Patel, Alan B Sandler, Joan H Schiller

Am J Clin Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.
Kyle W Robinson, Alan B Sandler

Oncologist· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials.
Suzanne E Dahlberg, Joan H Schiller, Philip B Bonomi, Alan B Sandler, Julie R Brahmer

J Thorac Oncol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EGFR tyrosine kinase inhibitors: difference in efficacy and resistance.
Kyle W Robinson, Alan B Sandler

Curr Oncol Rep· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond bevacizumab: antiangiogenic agents.
Shane Rogosin, Alan B Sandler

Clin Lung Cancer· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.
Giorgio V Scagliotti, Silvia Novello, Joan H Schiller, Vera Hirsh, Lecia V Sequist, Alan B Sandler

Clin Lung Cancer· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab.
Tien Hoang, Suzanne E Dahlberg, Alan B Sandler, Julie R Brahmer, Joan H Schiller

J Thorac Oncol· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction.
Nicholas W Choong, Ann M Mauer, Daniel C Haraf, Mark K Ferguson, Alan B Sandler

Med Oncol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III clinical trial development: a process of chutes and ladders.
David M Dilts, Steven K Cheng, Joshua S Crites, Alan B Sandler, James H Doroshow

Clin Cancer Res· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.
Suzanne E Dahlberg, Alan B Sandler, Julie R Brahmer, Joan H Schiller, David H Johnson

J Clin Oncol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.
Leora Horn, Suzanne E Dahlberg, Alan B Sandler, Afshin Dowlati, Dennis F Moore

J Clin Oncol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy.
Luigi Moretti, David S Yu, Heidi Chen, David P Carbone, David H Johnson, Alan B Sandler

Oncologist· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC).
Anshu K Jain, Randall S Hughes, Alan B Sandler, Afshin Dowlati, Lee S Schwartzberg

J Thorac Oncol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Steps and time to process clinical trials at the Cancer Therapy Evaluation Program.
David M Dilts, Alan B Sandler, Steven K Cheng, Joshua S Crites, Lori B Ferranti

J Clin Oncol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Angiogenesis in the treatment of non-small cell lung cancer.
Leora Horn, Alan B Sandler

Proc Am Thorac Soc· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.
Alan B Sandler, Joan H Schiller, Robert Gray, Isaiah Dimery, Julie Brahmer

J Clin Oncol· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
Robert Mutter, Bo Lu, David P Carbone, Ildiko Csiki, Luigi Moretti, Alan B Sandler

Clin Cancer Res· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Leora Horn, Alan B Sandler

Clin Lung Cancer· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer.
Hedy Lee Kindler, Howard A Burris, Alan B Sandler, Ira Anton Oliff

Invest New Drugs· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy.
Roy S Herbst, Thomas J Lynch, Alan B Sandler

Clin Lung Cancer· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
John V Heymach, Luis Paz-Ares, Filippo De Braud, Martin Sebastian, David J Stewart, Alan B Sandler

J Clin Oncol· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.
Lia Gore, Mace L Rothenberg, Cindy L O'Bryant, Mary Kay Schultz, Alan B Sandler

Clin Cancer Res· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.
Mary E R O'Brien, Mark A Socinski, Alexander Y Popovich, Igor N Bondarenko, Antoaneta Tomova, Alan B Sandler

J Thorac Oncol· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis